Analysts: Lilly faces 'ugly' period until its pipeline produces

Back to TopCommentsE-mailPrintBookmark and Share

For Eli Lilly and Co., it's going to get worse before it gets better.

Investors smiled on the Indianapolis-based drugmaker early last week when the company unveiled experimental cancer drugs and an aggressive play for the animal health market in China. But those smiles turned to frowns after Lilly disclosed surprisingly deep cuts to its U.S. sales force.

Lilly saw its stock price rise 2.7 percent from its closing price on April 9 until a peak on April 11—just after the news of the sales force layoffs broke.

That mini rally was fueled by a report out of China on April 8 that Lilly’s Elanco Animal Health unit had invested $100 million to acquire a 20-percent stake in China Animal Healthcare Ltd., and by Lilly’s release the next morning of new details about cancer drugs in its pipeline.

But when Lilly said it would cut roughly 1,000 salespeople—which is about 30 percent of its total U.S. sales force, according to the Wall Street Journal—the company's stock dropped 1.3 percent. Lilly shares closed Friday at $57.47 apiece.

Lilly's stock price has risen 45 percent in the past year, not counting its healthy dividend, mainly on rising hopes for the success of drugs in its pipeline.

“Lilly’s got some things in the pipeline, but until they actually see the light of day, they’re like a lot of people in pharma; they have to align costs with revenue,” said Les Funtleyder, a health care investing analyst at Polliwogg in New York City. He added, “I hope Lilly gets a few new drugs and then they can hire more people.”

In fact, Lilly does plan to submit as many as three new diabetes drugs for regulatory approval this year and, if approved, those drugs could lead the company to hire 300 salespeople, according to the Wall Street Journal, which cited a person familiar with the situation. Lilly has been trying to grow its diabetes, animal health and emerging markets' business units to counteract revenue it is losing from a string of patent expirations that began in 2010.

But the only certainties at this point are that Lilly will see two of its blockbuster drugs lose their U.S. patents in roughly the next year, which will sap $4.7 billion in annual sales as patients switch to cheaper generic versions of those drugs.

Losing patent protection will be antidepressant Cymbalta, Lilly’s best-seller, and the osteoporosis drug Evista.

Wall Street analysts still expect Lilly’s overall revenue to fall from $22.6 billion last year to as low as $20 billion in 2014. Lilly’s revenue already declined from an all-time high of $24.3 billion in 2011, after the patent expirations of its blockbuster cancer drug Gemzar in 2010 and its blockbuster antipsychotic Zyprexa in 2011.

“It is going to get a little ugly for Eli Lilly in this transition period,” said David Williamson, the health care analyst for the personal finance website Motley Fool. “If you believe in Eli Lilly’s pipeline, you shouldn’t be shaken by job cuts in the near term.”

In addition to diabetes, cancer is the other big category in which Lilly is trying to bring new drugs to market. Its leading experimental cancer drug candidate right now is ramucirumab, which it is studying as a treatment for gastric and breast cancer.

On April 10, Lilly also unveiled four early-stage drugs that it is studying as treatments for melanoma, lymphoma, non-small-cell lung cancer, ovarian cancer, gastric cancer, and cancers of the bile duct and liver.


  • Generic Olanzapine
    Generic Zyprexa (Olanzapine) still a cash cow Well, Lilly did make an astounding $70 billion to date on Zyprexa and sales off-patent are still at $2 billion year.Not a bad hunk of change.-Daniel Haszard Zyprexa patient who got diabetes from it's side effect

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. Angela IS the best RD

  2. We are a nation of speed. All of our younger lives are filled with deadlines, quotas and bottom lines. We start to ease out of the pressured rat-race when we finally see "retirement." The most enjoyable travel on the planet is passenger rail service. Indy to Chicago does not beat Megabus or Southwest Airlines in speed. Passenger rail however has the best seating, mammoth legroon, seat backs that recline to more than 45 degrees and employers that really want you to return as a customer. Indiana municipalities need to maintain subsidies to support this transportation mode. Losing it is loss for all of us.

  3. Good day! I just want to testify how i got my loan from Mr. Eric Lefkofsky after i applied several times from various loan lenders who claimed to also testify right in this forum,i thought the testimonies where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan. Until a friend of mine introduce me to this popular Mr. Eric Lefkofsky who promised to help me and indeed he did as he promised without any form of delay. I never thought there are still reliable loan lenders until i met Mr. Eric lefkofsky who indeed helped me with the loan and changed my belief. I promised to share this testimony after I got my loan. I don't know if you are in any way in need of a genuine and urgent loan,free feel to contact Mr. Eric Lefkofsky via their email{grouponfunding@hotmail.com}

  4. Its a THUG issue. Bleecker Street and NYX are thug bars. They attract thugs of all races. Places that attract thugs need to be kicked out of Broad Ripple. Ain't nobody got time for that!

  5. Hello everyone, My name is Marian Gareth, I am from the Texas, United State, am here to testify of how i got my loan from Mr Andre Frank {frankloancompany@yahoo.com} after i applied Two times from various loan lenders who claimed to be lenders right in this forum,i thought their lending where real and i applied but they never gave me loan. I was in need of an urgent loan to start a business and i applied from various loan lenders who promised to help but they never gave me the loan.Until a friend of mine introduce me to Mr Andre Frank the C.E.O of Andre Frank Loan Company who promised to help me with a loan of my desire and he really did as he promised without any form of delay, I never thought there are still reliable loan lenders until i met Mr Andre Frank, who really help me with my loan and changed my lief for better. I don't know if you are in need of an urgent loan, free feel to contact Mr Andre Frank on his email{ Frankloancompany@yahoo.com} for help